Targeted Oncology
Overview
Targeted Oncology is a peer-reviewed journal dedicated to advancing the understanding and treatment of cancer through targeted therapies. It provides comprehensive coverage of the latest research, clinical trials, and advancements in precision medicine, immunotherapy, and personalized treatment approaches. With a focus on targeted therapies, this journal serves as a valuable resource for oncologists, researchers, and healthcare professionals seeking to improve patient outcomes in the field of oncology.
Details
Details
Metrics
Metrics
h-index / Ranks: 6235
59
SJR / Ranks: 2146
1421
CiteScore / Ranks: 1874
8.80
JIF / Ranks: 1377
5.4
Recent Articles
1.
Mourlanette J, Rousseau-Bussac G, Mallah S, Guisier F, Zalcman G, Veillon R, et al.
Target Oncol
. 2025 Mar;
PMID: 40080277
Background: ROS1 chromosomic rearrangement is a rare oncogenic driver, and patients with this rearrangement benefit from specific targeted treatments in the first-line setting. However, therapeutic options are limited in pretreated...
2.
Garcia-Saenz J, Rodriguez-Lescure A, Cruz J, Albanell J, Alba E, Llombart A
Target Oncol
. 2025 Mar;
PMID: 40059257
No abstract available.
3.
Shatila M, Eshaghi F, Colli Cruz C, Machado A, Mathew A, Zhao D, et al.
Target Oncol
. 2025 Mar;
PMID: 40038186
Background: Immune-checkpoint inhibitors (ICIs) enhance the immune response against cancer but can cause immune-related adverse events, with immune-mediated colitis (IMC) being among the most common. Objective: We investigated variations in...
4.
Miklos D, Riedell P, Bokun A, Chavez J, Schuster S
Target Oncol
. 2025 Mar;
PMID: 40035913
Standard treatment options for B cell malignancies include immunochemotherapies and/or targeted therapies, which often provide temporary disease remission. However, many patients do not achieve complete remission with these treatments, develop...
5.
Ampolini E, Jimenez-Sainz J, Long D
Target Oncol
. 2025 Mar;
PMID: 40024979
The ataxia-telangiectasia mutated (ATM) protein kinase plays a critical role in activating the cellular response to DNA double-strand breaks and promoting homology-directed repair. ATM is frequently mutated in cancer, contributing...
6.
Elmeliegy M, Viqueira A, Vandendries E, Hickman A, Conte U, Irby D, et al.
Target Oncol
. 2025 Feb;
PMID: 40000533
Background: Elranatamab is a BCMA-CD3 bispecific antibody approved for the treatment of relapsed or refractory multiple myeloma. Cytokine release syndrome is one of the most common adverse events associated with...
7.
Camera S, Rossari F, Foti S, Vitiello F, Persano M, Prinzi F, et al.
Target Oncol
. 2025 Feb;
PMID: 39985696
Biliary tract cancers (BTCs) are a wide class of malignancies with dismal prognosis. The therapeutic scenario of metastatic BTCs has profoundly changed during recent years. The combination of cisplatin-gemcitabine plus...
8.
Shatila M, Machado A, Shah J, Rivera A, Naz S, Glombicki S, et al.
Target Oncol
. 2025 Feb;
PMID: 39904838
Background: Stem cell transplantation (SCT) and immune checkpoint inhibitors (ICIs) are both used in the treatment of hematological malignancies. There may be an overlap in patient exposure to both treatments....
9.
Brazel D, Smith J, Ou S, Nagasaka M
Target Oncol
. 2025 Feb;
PMID: 39903428
Targeted therapies have revolutionized treatment of non-small-cell lung cancer (NSCLC); however, epidermal growth factor receptor (EGFR) exon20ins mutations are resistant to tyrosine kinase inhibitors. Amivantamab utilizes multiple mechanisms of action...
10.
Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options
Mettias S, ElSayed A, Moore J, Berenson J
Target Oncol
. 2025 Jan;
PMID: 39878864
Multiple myeloma (MM) is a bone-marrow-based cancer of plasma cells. Over the last 2 decades, marked treatment advances have led to improvements in the overall survival (OS) of patients with...